[Radioimmunoimaging (RII) and radioimmunotherapy (RIT) of human primary hepatic cancer (hPHC) with anti-PHC monoclonal antibody in tumor bearing nude mice].

Tumor xenografts of human PHC were grown in nude mice subcutaneously. The studies were performed in nude mice with tumor base aear of 0.8cm-1.0cm. For the study of RII, the mice were injected intravenously with 1.11 x 10(7)Bq/mouse of 131I-hepama-1. All tumours were clearly visualied on the 4th day after injection and remained the same until the 7th day. No tumor image was found in 131I-mIgG. The tumor to liver ratio of radioactivity increased from 1.3 to 3.03 in 131I-Hepama-1 group, but decreased from 13.6 to 6.88% in 131I-mIgG group. For the study of RIT 131I-hepama-1 (1.85 x 10(10)Bq) was administered intraperitoneally. A tumor growth inhibition rate at the 4th week after the infusion of 70.5% was obtained. The median survival time of the nude mice in 131I-hepama-1 group was much longer than in control groups in mice.